We are pleased to announce our partnership with NeoVirTech!
NeoVirTech and VirHealth join their virology expertise to provide customers one of the most extended virus disinfection measurement and R&D platform in France and in Europe. This alliance will allow the partners to combine their
respective expertise in an integrated offer dedicated to increase knowledge in virus persistence in the environment, virus disinfection procedure and to provide customer state of the art models for the measurement of disinfection
procedures using innovative and standardized approaches.
Surfaces with antiviral activities participate in the management of viral contamination by reducing
the infectious virus load over time. We offer standardized or adapted protocols to evaluate the
antiviral efficacy of porous and non-porous surfaces on a large panel of viruses (enveloped and non-
enveloped) including alpha/beta coronaviruses.
Our last preprint on the role of interfering substances on SARS-CoV-2 surface stability and virucidal efficiency of hand sanitizers and disinfectants is now available in MedRxiv.
https://www.medrxiv.org/content/10.1101/2020.08.22.20180042v1
Contaminated environmental surfaces are considered to represent a significant vector for hospital-acquired viral infections and indirect contact transmission involving these surfaces could be the predominant transmission route for respiratory viruses. In collaboration with #VirPath, #VirHealth has used both EN14476 and EN16777 standardized protocols for evaluation of virucidal activity using tailor-made interfering substances corresponding to artificial mixture containing nasal mucus and saliva. They reflect current “real life” conditions of use by considering the impact of omnipresent secretions from coughing or sneezing. In this study, we have measured surface stability of SARS-CoV-2 and other coronavirus in different experimental conditions and demonstrated that interfering substances (nasal mucus, saliva) play an important role in the virucidal efficiency of disinfectants.
Since 2015, VirHealth has been working in partnership with Virpath laboratory (Dr Rosa-Calatrava,
CIRI, Lyon) as part of a research and innovation program in order to answer the institutions and
manufacturers needs during health crises and viral epidemics/pandemics (Avian Influenza, MERS-
CoV coronavirus,…).
Since March 2020, we have been jointly carrying out virucidal activity tests of disinfection products and equipment on Sars-Cov-2 (COVID-19). We also lead applied research programs to better understand
the virus biology and offer technical approaches for setting up appropiate testing strategies.
Photo credit : Virpath (CIRI), Dr Rosa-Calatrava.